Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Accuracy of artificial intelligence compared to trained medical technologists in diabetic retinopathy screening].

Revista medica de Chile·2021
Same author

Aqueous shunt versus trabeculectomy for treatment of glaucoma.

Medwave·2018
Same author

Natamycin versus voriconazole for fungal keratitis.

Medwave·2018
Same author

[Experience in visceral cutaneous and cutaneous loxoscelism of hospital management: clinical, evolution and therapeutic proposal].

Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia·2018
Same author

Is ustekinumab effective for psoriatic arthritis with insufficient response to initial treatment?

Medwave·2018
Same author

Is secukinumab effective for psoriatic arthritis with insufficient response to initial treatment?

Medwave·2017

Related Experiment Video

Updated: Feb 1, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K

Secukinumab for plaque psoriasis.

Gonzalo Ordenes-Cavieres1, Romina Andino-Navarrete2

  • 1Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Proyecto Epistemonikos, Santiago, Chile.

Medwave
|December 4, 2018
PubMed
Summary
This summary is machine-generated.

Secukinumab offers clinical improvement for plaque psoriasis patients unresponsive to traditional therapies. However, this biological treatment may be linked to serious adverse effects, necessitating careful consideration.

Keywords:
EpistemonikosGRADEbiological treatmentssecukinumabPlaque psoriasis

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

935
Plaquing of Herpes Simplex Viruses
04:41

Plaquing of Herpes Simplex Viruses

Published on: November 5, 2021

7.1K

Related Experiment Videos

Last Updated: Feb 1, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

935
Plaquing of Herpes Simplex Viruses
04:41

Plaquing of Herpes Simplex Viruses

Published on: November 5, 2021

7.1K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Biological treatments are key for plaque psoriasis management in non-responders to conventional therapies.
  • Evaluating the efficacy and safety of these advanced treatments is crucial for clinical practice.

Purpose of the Study:

  • To systematically evaluate the efficacy and safety of biological treatments for plaque psoriasis.
  • To synthesize evidence from randomized controlled trials on secukinumab's effectiveness and risks.

Main Methods:

  • A comprehensive search of Epistemonikos database, including MEDLINE, EMBASE, and Cochrane.
  • Data extraction from 21 systematic reviews, reanalysis of primary studies, and meta-analysis.
  • Application of the GRADE approach for summarizing findings on efficacy and safety.

Main Results:

  • Included ten randomized trials across 21 systematic reviews.
  • Secukinumab demonstrated clinical improvement in patients with plaque psoriasis.
  • Potential association with serious adverse effects was identified.

Conclusions:

  • Secukinumab is effective in achieving clinical improvement for plaque psoriasis.
  • The treatment's safety profile indicates a probable association with serious adverse effects.
  • Further research and careful patient selection are warranted for optimal use.